- Home
- CYTH
as 11-22-2024 10:32am EST
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | GAINESVILLE |
| Market Cap: | 20.4M | IPO Year: | N/A |
| Target Price: | $0.95 | AVG Volume (30 days): | 21.2K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $2.12 | Next Earning Date: | 11-14-2024 |
| Revenue: | $870,725 | Revenue Growth: | -8.52% |
| Revenue Growth (this year): | -8.43% | Revenue Growth (next year): | 24.49% |
Latest Cyclo Therapeutics Inc. News
CYTH Breaking Stock News: Dive into CYTH Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
16 days ago
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
GlobeNewswire
a month ago
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Business Wire
3 months ago
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
GlobeNewswire
3 months ago
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Simply Wall St.
3 months ago
Cyclo Therapeutics Second Quarter 2024 Earnings: Misses Expectations
Business Wire
3 months ago
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Business Wire
4 months ago
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
Compare CYTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTH Cyclo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.